Candel Therapeutics (CADL) to Release Earnings on Tuesday

Candel Therapeutics (NASDAQ:CADL) is expected to be announcing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($0.2958) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 9:30 AM ET.

Candel Therapeutics (NASDAQ:CADL) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.30). On average, analysts expect Candel Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Candel Therapeutics Trading Up 3.6%

Candel Therapeutics stock traded up $0.27 during trading hours on Tuesday, hitting $7.80. The company had a trading volume of 1,250,550 shares, compared to its average volume of 1,281,474. The firm has a market cap of $571.73 million, a P/E ratio of -11.02 and a beta of -0.59. The company has a debt-to-equity ratio of 0.91, a quick ratio of 13.49 and a current ratio of 13.49. Candel Therapeutics has a 1 year low of $4.34 and a 1 year high of $7.99. The company has a 50-day moving average price of $5.31 and a two-hundred day moving average price of $5.44.

Insider Buying and Selling

In other news, Director Paul B. Manning bought 550,458 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was bought at an average price of $5.45 per share, with a total value of $2,999,996.10. Following the completion of the transaction, the director directly owned 2,763,527 shares of the company’s stock, valued at approximately $15,061,222.15. The trade was a 24.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 16.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its position in Candel Therapeutics by 128.2% during the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after acquiring an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after purchasing an additional 7,527 shares in the last quarter. Invesco Ltd. acquired a new position in Candel Therapeutics during the 1st quarter valued at approximately $59,000. The Manufacturers Life Insurance Company acquired a new position in Candel Therapeutics during the 2nd quarter valued at approximately $70,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Candel Therapeutics by 37.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after purchasing an additional 4,583 shares in the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CADL shares. Cantor Fitzgerald started coverage on shares of Candel Therapeutics in a research report on Monday, April 20th. They issued an “overweight” rating for the company. Citigroup lowered their price objective on shares of Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Monday, April 20th. Zacks Research cut shares of Candel Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 price objective on shares of Candel Therapeutics in a research report on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $18.00.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.